VIDAC PHARMA HOLDING PLC
Commented by Nico Popp on April 25th, 2025 | 07:20 CEST
US biotechs under pressure – Where opportunities now lie: BioNTech, Pfizer, and Vidac Pharma
The biotech world is in turmoil. The dispute between US President Donald Trump and the elite Harvard University is just the tip of the iceberg – thousands of researchers in the US are upset about the interference in their academic freedom. Research funding is being cut because of supposedly incorrect wording in applications. Entire degree programs are being put on hold because they do not fit into the worldview of the new US administration. The National Security Commission on Emerging Biotechnology (NSCEB) is warning of dire consequences for the US economy. Is the United States losing its status as a biotech mecca?
Read
Commented by André Will-Laudien on April 11th, 2025 | 07:15 CEST
Trump rally boosts Vidac Pharma: Further milestones in cancer research achieved!
Humanity continues to fight relentlessly against cancer. As one of the most common causes of death, researchers have been trying to unravel the secrets of this terrible disease for more than 175 years. Meanwhile, early detection and forms of therapy have come a long way, and many patients diagnosed with cancer often go on to live for many years after their diagnosis. However, it is still too early for triumph; progress is incremental and costs time and money. The dream of biotech investors is to find the needle in the haystack. Which publicly listed company will achieve the long-awaited breakthrough? Vidac Pharma has so far achieved recognized milestones and continues its research in a targeted manner. According to a recent study on the Company, investors could see a tenfold increase over the next few years. This is reason enough for us to take a closer look!
Read
Commented by Fabian Lorenz on April 3rd, 2025 | 07:20 CEST
Stock set for 100% rally! Evotec, thyssenkrupp, Vidac Pharma - A golden April ahead?
Can shareholders look forward to a 100% price gain soon? If analysts have their way, this could be imminent for Evotec. However, shareholders must first mark an important date in April, as the medium-term share price performance is likely to be decided then. For Vidac Pharma, analysts see even greater upside potential, making the current price weakness an interesting entry opportunity. After all, the biotech company is making operational progress. One of the surprises of the current week is thyssenkrupp. The Company is benefiting from billions being spent in defense and infrastructure. Now, it could also benefit from Trump's tariff policies. Analysts recommend buying.
Read
Commented by Stefan Feulner on March 24th, 2025 | 07:20 CET
Bayer, Vidac Pharma, BioNTech – Setbacks and New Standards
Glyphosate and no end in sight. Bayer's 2018 acquisition of US agricultural company Monsanto continues to develop into a billion-dollar grave, with a court again ruling against the Leverkusen-based company. Billions in revenue also disappeared from the books of vaccine manufacturer BioNTech after the COVID-19 pandemic subsided. In contrast, an innovative biopharmaceutical company is setting new standards in treating pediatric brain tumors.
Read
Commented by Armin Schulz on March 18th, 2025 | 07:00 CET
Bayer, Vidac Pharma, BioNTech – Making money with biotech and pharmaceutical innovations
More and more investors are betting on companies that are leaving traditional therapeutic paths to rethink cancer, chronic inflammation, or nutritional issues. While some corporations struggle with their balance sheets due to mountains of debt and patent expirations, others are quietly developing technologies that crack the metabolic code of diseases. Whether anti-aging tests from saliva samples, mRNA-based cancer cocktails, or active ingredients that overcome the blood-brain barrier – the stock market rewards those who combine research success with strategic risk-taking. But which companies have what it takes to develop the blockbusters of tomorrow? Let's take a closer look at three companies.
Read
Commented by Juliane Zielonka on March 7th, 2025 | 06:45 CET
Bayer, Vidac Pharma, Xiaomi: What matters now for your health
Innovative solutions to improve the quality of life for millions of patients are the focus of a new generation of companies that are breaking new ground in research and technology. The German company Bayer is reporting impressive results for 2024 in its pharmaceutical division with Nubeqa™ for prostate cancer and plans to increase its sales to over EUR 2.5 billion in 2025. The biopharmaceutical company Vidac Pharma, currently in the clinical phase, specializes in the fight against tumors and is making progress in a Phase 2b study against actinic keratosis with the active ingredient VDA-1102. The Chinese tech company Xiaomi scores with smart health monitoring with products like the Watch S4. It also connects households and has expanded its Internet of Things ecosystem to millions of connected devices. These approaches – whether in medicine, cancer therapy, or health technology – offer progress for patients, users, and potential for investors who are focusing on sustainable growth. How are these companies shaping the future?
Read
Commented by André Will-Laudien on February 27th, 2025 | 07:50 CET
Attention – Biotech is taking off! Evotec, Vidac Pharma, BioNTech, and Novo Nordisk in focus
With new index highs and huge daily trading volumes, the biotech sector has been back in the spotlight for several weeks. At Evotec, the personnel merry-go-round continues, while BioNTech has announced an acquisition in the oncology field. After the big crash in Novo Nordisk shares, the first share buybacks are now taking place, but growth rates have been revised downwards. Vidac Pharma has just completed a roadshow and will present its latest progress at the Sachs Health Science CEOs Forum in Zurich. Share prices across the sector appear to have turned in the last quarter. It is now time for investors to take a closer look again. We offer a few insights.
Read
Commented by Armin Schulz on February 19th, 2025 | 07:10 CET
Bayer, Vidac Pharma, Pfizer – Dementia, cancer, obesity: The race for the billion-dollar markets
The pharmaceutical industry is in the throes of a major upheaval – it is no longer just about research but also about big money. Whoever is ahead now secures not only fame but, above all, extremely lucrative markets. Looking at how companies are currently driving forward mergers or acquiring startups, it is clear: The battle for the next blockbuster drugs has long since become a billion-dollar gamble. There is a lot of activity, especially in areas such as cancer, dementia, and obesity. Everyone wants to be the first to patent the golden active ingredient. We take a look at three companies that are researching the next blockbusters.
Read
Commented by Fabian Lorenz on February 13th, 2025 | 07:10 CET
ACQUISITION?! Renk, BioNTech, and Biotech Highflyer Vidac Pharma
Is Renk about to be taken over? Quite possible. The Company, known for its transmissions for the Leopard tank, has a new major shareholder. And it turns out to be none other than KNDS – the maker of the Leopard 2 tank. The Renk share price reacted with a jump of 10%. Is there more to come? Vidac Pharma is also frequently mentioned as a potential takeover candidate. Like BMW, the Company is working on a "new class". But in this case, it is to save human lives. To this end, last year's biotech highflyer aims to revolutionize cancer treatment. Experts believe that a multiplication of the share price is possible. BioNTech is also fighting cancer. In addition to its own research, the German company is strategically focusing on acquisitions. Another one has just been completed. What is next?
Read
Commented by Juliane Zielonka on January 31st, 2025 | 06:55 CET
Vidac Pharma, Bayer AG, Novo Nordisk: Three companies that will shape the pharmaceutical landscape in 2025
The pharmaceutical industry is again demonstrating its market power between innovation and risk: Vidac Pharma reports a milestone in colorectal cancer therapy with VDA1275. The combination of the active ingredient with a chemotherapeutic agent achieves a 38.9% tumor reduction in preclinical studies. This synergy effect raises hope for gentler chemotherapy treatments and more innovative approaches. Bayer AG is making waves at the JP Morgan Health Conference with its pharmaceutical pipeline: the prostate cancer drug Nubeqa™ achieves blockbuster status with revenue of EUR 1 billion. In women's health, the first non-hormonal therapy for menopausal symptoms is expected to reach the US market as early as 2025. Novo Nordisk, on the other hand, is threatened with a class-action lawsuit in the billion-dollar market for obesity drugs: the REDEFINE-1 study on the promising drug CagriSema revealed weaknesses in the study design. After the results were made public, the share price fell by 18%. While Vidac Pharma and Bayer impress with precise study results, the Novo Nordisk case shows the fragility of methodological fuzziness. The details.
Read